当前位置: X-MOL 学术Protein Sci. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
RCSB Protein Data Bank: Enabling biomedical research and drug discovery.
Protein Science ( IF 8 ) Pub Date : 2019-11-29 , DOI: 10.1002/pro.3730
David S Goodsell 1, 2, 3 , Christine Zardecki 1, 2 , Luigi Di Costanzo 1, 2 , Jose M Duarte 4 , Brian P Hudson 1, 2 , Irina Persikova 1, 2 , Joan Segura 4 , Chenghua Shao 1, 2 , Maria Voigt 1, 2 , John D Westbrook 1, 2 , Jasmine Y Young 1, 2 , Stephen K Burley 1, 2, 4, 5
Affiliation  

Analyses of publicly available structural data reveal interesting insights into the impact of the three-dimensional (3D) structures of protein targets important for discovery of new drugs (e.g., G-protein-coupled receptors, voltage-gated ion channels, ligand-gated ion channels, transporters, and E3 ubiquitin ligases). The Protein Data Bank (PDB) archive currently holds > 155,000 atomic-level 3D structures of biomolecules experimentally determined using crystallography, nuclear magnetic resonance spectroscopy, and electron microscopy. The PDB was established in 1971 as the first open-access, digital-data resource in biology, and is now managed by the Worldwide PDB partnership (wwPDB; wwPDB.org). US PDB operations are the responsibility of the Research Collaboratory for Structural Bioinformatics PDB (RCSB PDB). The RCSB PDB serves millions of RCSB.org users worldwide by delivering PDB data integrated with ∼40 external biodata resources, providing rich structural views of fundamental biology, biomedicine, and energy sciences. Recently published work showed that the PDB archival holdings facilitated discovery of ∼90% of the 210 new drugs approved by the US Food and Drug Administration 2010-2016. We review user-driven development of RCSB PDB services, examine growth of the PDB archive in terms of size and complexity, and present examples and opportunities for structure-guided drug discovery for challenging targets (e.g., integral membrane proteins).

中文翻译:

RCSB蛋白质数据库:支持生物医学研究和药物发现。

对公开可用结构数据的分析揭示了对蛋白质靶标的三维(3D)结构的影响的有趣见解,这些蛋白质靶标对于发现新药非常重要(例如,G蛋白偶联受体,电压门控离子通道,配体门控离子通道,转运蛋白和E3泛素连接酶)。蛋白质数据库(PDB)档案库目前拥有超过155,000个原子级3D结构的生物分子,这些结构是通过晶体学,核磁共振波谱和电子显微镜实验确定的。PDB成立于1971年,是生物学中第一个开放获取的数字数据资源,现在由Worldwide PDB合作伙伴(wwPDB; wwPDB.org)管理。美国PDB的运作由结构生物信息学PDB研究合作社(RCSB PDB)负责。RCSB PDB通过提供与约40种外部生物数据资源集成的PDB数据,为全球数百万RCSB.org用户提供服务,提供了基础生物学,生物医学和能源科学的丰富结构视图。最近发表的工作表明,PDB档案馆藏促进了美国食品药品监督管理局2010-2016年批准的210种新药中约90%的发现。我们审查了由用户驱动的RCSB PDB服务的开发,从大小和复杂性方面检查了PDB档案的增长,并提供了针对具有挑战性的靶标(例如,整合膜蛋白)的结构指导药物发现的实例和机会。最近发表的工作表明,PDB档案馆藏促进了美国食品药品监督管理局2010-2016年批准的210种新药中约90%的发现。我们审查了由用户驱动的RCSB PDB服务的开发,从大小和复杂性方面检查了PDB档案的增长,并提供了针对具有挑战性的靶标(例如,整合膜蛋白)的结构指导药物发现的实例和机会。最近发表的工作表明,PDB档案馆藏促进了美国食品药品监督管理局2010-2016年批准的210种新药中约90%的发现。我们审查了由用户驱动的RCSB PDB服务的开发,从大小和复杂性方面检查了PDB档案的增长,并提供了针对具有挑战性的靶标(例如,整合膜蛋白)的结构指导药物发现的实例和机会。
更新日期:2019-12-21
down
wechat
bug